G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Trajectory Through 2024-2033

Spread the love

The G-CSF (Granulocyte Colony Stimulating Factors) by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The G-CSF (Granulocyte Colony Stimulating Factors) Market:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

According to The Business Research Company’s G-CSF (Granulocyte Colony Stimulating Factors), The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical r&d expenditure and government initiatives.

The g-csf (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (g-csf), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs. Major trends in the forecast period include investing extensively in r&d activities for the development of effective and innovative drugs, increasing focus on m&a growth strategies to expand the customer base and geographic markets, establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. G-CSF (granulocyte colony stimulating factor) is a class of growth factors that produce white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF (granulocyte colony stimulating factor) market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product: Tablet, Capsule, Other Products

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Companies in the G-CSF (granulocyte colony stimulating factor) market are focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For example, in 2022, Evive Biotech, a Singapore-based biopharmaceutical company collaborated with Germany based pharmaceutical company, APOGEPHA to enter into an exclusive long-term license agreement for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a novel dimeric G-CSF long-acting fusion protein without pegylation.

The g-csf (granulocyte colony stimulating factors) market report table of contents includes:

Executive Summary
G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics
G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies
G-CSF (Granulocyte Colony Stimulating Factors) Market – Macro Economic Scenario
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size and Growth

Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Benchmarking
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Dashboard
Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market
G-CSF (Granulocyte Colony Stimulating Factors) Market Future Outlook and Potential Analysis
Appendix

Top Major Players: